Glaucoma and Injection site extravasation

Summary:

Injection site extravasation is found among people with Glaucoma, especially for people who are female, 60+ old.

The study analyzes which people have Injection site extravasation with Glaucoma. It is created by eHealthMe based on reports of 19 people who have Glaucoma from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Glaucoma?

Glaucoma (increased fluid pressure in the eye with vision loss) is found to be associated with 1,236 drugs and 1,654 conditions by eHealthMe. Check the latest studies of Glaucoma.

What is Injection site extravasation?

Injection site extravasation (flow of (blood or lymph) from injection site) is found to be associated with 556 drugs and 726 conditions by eHealthMe. Check the latest studies of Injection site extravasation.

On Jul, 13, 2026

19 people who have Glaucoma and Injection Site Extravasation are studied.

Would you have Injection site extravasation when you have Glaucoma?

Gender of people who have Glaucoma and experienced Injection Site Extravasation *:

female: 72.22 %
male: 27.78 %

Age of people who have Glaucoma and experienced Injection Site Extravasation *:

Common co-existing conditions for these people *:

High Blood Cholesterol: 8 people, 42.11%
Type 2 Diabetes: 8 people, 42.11%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 36.84%
Pain: 5 people, 26.32%
High Blood Pressure: 4 people, 21.05%
Diabetes: 3 people, 15.79%
Depression: 2 people, 10.53%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 10.53%
Breast Cancer: 2 people, 10.53%
Thyroid Diseases: 2 people, 10.53%

Common drugs taken by these people *:

Bydureon: 8 people, 42.11%
Humira: 6 people, 31.58%
Metformin: 5 people, 26.32%
Methotrexate: 5 people, 26.32%
Prednisone: 4 people, 21.05%
Folic Acid: 3 people, 15.79%
Lantus: 2 people, 10.53%
Atorvastatin Calcium: 2 people, 10.53%
Betaxolol Hydrochloride: 2 people, 10.53%
Bydureon Bcise: 2 people, 10.53%

Common symptoms for these people *:

Injection Site Pain: 5 people, 26.32%
Injection Site Haemorrhage (bleeding from injection site): 4 people, 21.05%
Weight Decreased: 3 people, 15.79%
Pain In Extremity: 2 people, 10.53%
Onychomadesis (a periodic idiopathic shedding of the nails): 2 people, 10.53%
Blood Glucose Decreased: 2 people, 10.53%
Injection Site Nodule (small swelling or aggregation of cells in the body, esp. an abnormal one at injection site): 2 people, 10.53%
Tremor (trembling or shaking movements in one or more parts of your body): 1 person, 5.26%
Tumor: 1 person, 5.26%
Abdominal Pain: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Injection site extravasation?

- Check whether Injection site extravasation is associated with a drug or a condition

Related publications that referenced our studies

Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .
Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .

Related studies:

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Injection site extravasation and Glaucoma, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.